Search clinical trials for: Cholestatic

Total 43 results

Hospital Pediátrico de Sinaloa

Recruiting

Parenteral Nutrition Cycling for Prevention of Cholestatic Syndrome in Newborn

Cholestasis in Newborn

Mexico
Xi'An Aolitai Pharmaceutical Technology Co Ltd

Recruiting

A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in DILI Subjects

Drug-Induced Liver Injury | Cholestatic Liver Injury | Mixed Liver Injury

China
Children's Hospital of Fudan University

Not yet recruiting

Application and Effect Evaluation of Medium Chain Fatty Acid Rich Milk Powder in Infants With Cholestatic Liver Disease

Cholestatic Liver Disease

China
Escient Pharmaceuticals, Inc

Recruiting

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis (PACIFIC)

Pruritus

United States, United Kingdom, Belgium, Israel, Spain, Canada, France, Netherlands
Zydus Therapeutics Inc.

Recruiting

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

Cirrhosis | Hepatic Impairment | Cholestatic Liver Disease

United States
Zydus Therapeutics Inc.

Recruiting

Hepatic Impairment, Cholestatic Liver Disease, & NASH With Advanced Fibrosis & Normal Hepatic Function

Hepatic Impairment

United States
GlaxoSmithKline

Recruiting

Linerixibat Long-term Safety, and Tolerability Study (LLSAT)

Cholestasis

United States, France, Japan, United Kingdom, Bulgaria, Germany, Greece, Italy, China, Argentina, Belgium, Brazil, Canada, Czechia, Israel, Mexico, Poland, Russian Federation, Spain, Switzerland
Mayo Clinic

Recruiting

Biobank for Cholestatic Liver Diseases.

Cholangiocarcinoma | Primary Sclerosing Cholangitis | Liver Cancer | Primary Biliary Cirrhosis

United States
Beijing Friendship Hospital
Peking University First Hospital; Fudan University; Beijing YouAn Hospital; Beijing... and other collaborators

Recruiting

China Registry for Genetic / Metabolic Liver Diseases

Genetic/Metabolic Liver Diseases

China
Arbor Research Collaborative for Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) (LOGIC)

Liver Diseases | Alpha 1-Antitrypsin Deficiency | Alagille Syndrome

United States, Canada
Duke University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Drug-Induced Liver Injury (DILI) Network Retrospective (ILIAD)

Drug Induced Liver Injury

United States
Duke University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

DILIN - Prospective Study

Liver Diseases

United States
Mayo Clinic

Active, not recruiting

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

United States
Mirum Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). (RISE)

Cholestatic Liver Disease | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis

United States, United Kingdom, France, Belgium, Poland, Brazil, Mexico
Mayo Clinic

Active, not recruiting

Genomics of Primary Sclerosing Cholangitis (PSC)

Primary Sclerosing Cholangitis (PSC)

United States
Albireo

Completed

An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects

Primary Biliary Cirrhosis | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis | Orphan Cholestatic Liver Diseases

United Kingdom
Albireo

Completed

A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384

Primary Biliary Cirrhosis | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis | Orphan Cholestatic Liver Diseases
Mirum Pharmaceuticals, Inc.

Active, not recruiting

MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study (MERGE)

Cholestatic Liver Disease

United States, France, United Kingdom, Canada, Belgium, Poland, Australia, Spain
Children's Hospital Medical Center, Cincinnati

Active, not recruiting

Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease

Cholestasis | Red Cell Membrane and Enzyme Abnormalities

United States
Arbor Research Collaborative for Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE) (FORCE)

Portal Hypertension | Cholestasis | Liver Fibrosis | Biliary Atresia | Alagille Syndrome | Alpha1 Anti-Trypsin Deficiency

United States, Canada
GlaxoSmithKline

Available

Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)

Pruritus
Mirum Pharmaceuticals, Inc.

Completed

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis (INDIGO)

Progressive Familial Intrahepatic Cholestasis (PFIC)

United States, United Kingdom, Poland, France
Cara Therapeutics, Inc.

Terminated

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

Cholestatic Pruritus

United States
Escient Pharmaceuticals, Inc
Novotech (Australia) Pty Limited

Completed

Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus

Pruritus | Cholestasis | Kidney Failure

Australia, New Zealand
Indonesia University

Active, not recruiting

Probiotics in Pediatric Chronic Cholestasis

Cholestatic Liver Disease

Indonesia
Children's Hospital of Fudan University

Withdrawn

BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases

Cholestasis, Intrahepatic | Hereditary Diseases
Mirum Pharmaceuticals, Inc.

Completed

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) (IMAGINE)

Alagille Syndrome

United Kingdom
Mirum Pharmaceuticals, Inc.
Clinigen, Inc.

Approved for marketing

A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)

Alagille Syndrome

United States
Mirum Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc.; Childhood Liver Disease Research and Education...

Completed

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome (IMAGINE-II)

Alagille Syndrome

United States, Canada
University of Birmingham
University Hospital Birmingham NHS Foundation Trust; Intercept Pharmaceuticals

Terminated

EXerCise Intervention in cholesTatic LivEr Disease: The EXCITED Study (EXCITED)

Primary Biliary Cholangitis

United Kingdom
Celgene

Terminated

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Pancreatic Neoplasms | Cholestasis

United States, Germany
Mirum Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome (IMAGO)

Alagille Syndrome

United Kingdom
Mirum Pharmaceuticals, Inc.

Completed

Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease

Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis

United States, Canada
University of Tennessee
University of Colorado, Denver; Baylor College of Medicine; Children's Hospital... and other collaborators

Completed

Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis

United States
Sahlgrenska University Hospital, Sweden
Albireo

Terminated

IBAT Inhibitor A4250 for Cholestatic Pruritus

Biliary Cirrhosis, Primary

Sweden
Academisch Medisch Centrum - Universiteit van Amsterdam...
Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaborators

Unknown

The Effect of Bezafibrate on Cholestatic Itch (FITCH)

Primary Sclerosing Cholangitis | Primary Biliary Cholangitis | Secondary Sclerosing Cholangitis

Netherlands, Spain
Tischendorf, Jens, M.D.

Completed

Endoscopic Ultrasound as an Early Diagnostic Tool for Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis

Germany
Beijing Trendful Kangjian Medical Information Consulting...

Completed

Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC

Cholestatic Liver Disease

China
Foundation for Liver Research

Completed

Colesevelam Versus Placebo in Cholestatic Pruritus (COPE)

Chronic Liver Disease

Netherlands
Taipei Veterans General Hospital, Taiwan

Unknown

Cholestatic Drug-induced Liver Injury (DILI)

Hepatitis, Toxic

Taiwan
National Institute of Diabetes and Digestive and...

Completed

Treatment of Cholestatic Pruritus With Sertraline

Hepatitis C | Pruritus | Liver Cirrhosis, Biliary

United States
National Center for Research Resources (NCRR)
Children's Hospital Medical Center, Cincinnati

Completed

Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease

Cholestasis | Biliary Atresia | Alagille Syndrome

United States
National Center for Research Resources (NCRR)
Children's Hospital Medical Center, Cincinnati

Unknown

Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease

Gastrointestinal Diseases | Cystic Fibrosis | Cholestasis

United States

Search clinical trials for: Cholestatic

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations